Investigation of The Prevalence of Sepsis in Adults in Multicenter Intensive Care Unıts in Turkey

Sepsis Clinical Trial

Official title:

Investigation of The Prevalence of Sepsis in Adults in Multicenter Intensive Care Unıts in Turkey

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03179189
• Other study ID #: 2017/77
• Status: Recruiting
• Phase: N/A
• First received: June 6, 2017
• Last updated: September 27, 2017
• Start date: October 1, 2017
• Est. completion date: March 1, 2018

Study information

• Verified date: September 2017
• Source: Izmir Ataturk Training and Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The pathophysiology and treatment of sepsis disease are still not fully known. International guides often refer to the studies done in the developed countries and suggest some treatments. The infrastructure of the developing countries is quite different. For this reason, it is not exactly scientific how much these proposals are reflected in patient treatment. In our study, We will try to reveal the treatment of sepsis.

Description:

Sepsis is a clinical syndrome that has physiologic, biologic, and biochemical abnormalities caused by a dysregulated inflammatory response to infection. Sepsis and the inflammatory response that ensues can lead to multiple organ dysfunction syndrome and death. In the late 1970s, it was estimated that 164,000 cases of sepsis occurred in the United States (US) each year. Since then, rates of sepsis in the US and elsewhere have dramatically increased as supported by the following studies, although many of these are derived from academic institutions. The increased rate of sepsis is thought to be a consequence of advancing age, immunosuppression, and multidrug-resistant infection. It is also likely to be due to the increased detection of early sepsis from aggressive sepsis education and awareness campaigns, although this hypothesis is unproven. Guidelines should focus on pre-hospital assessment and triage. Indeed, respiratory infections represented the most common cause of sepsis in that cohort, and postoperative infections were another important part of the problem. Whether these conditions apply to patients with shock in low-income and middle-income countries (LMIC) is unknown, but the incidence of community-acquired infections would be higher, with a greater prevalence of gastroenteritis, septic abortion, and skin and soft tissue infections as causes of septic shock. The bacteriology of bloodstream infections across LMICs varies substantially depending on regional and population characteristics. In a meta-analysis of 19 prospective studies on community-acquired bacteraemia in Africa, the most common organisms isolated were Salmonella spp (predominantly non-typhi), Streptococcus pneumoniae, and Gram-negative organisms such as Escherichia coli.11 Among cases for which mortality data were recorded, patients with bloodstream infections had an average mortality of 21.5%. Although data are lacking, appropriate antibiotic treatment for these infections on the basis of bacterial resistance patterns will ultimately depend on the ecological pressures resulting from local antibiotic availability and patterns of use.

We aimed to evaluate the approach to sepsis in Turkey as a multi-centered study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: March 1, 2018
• Est. primary completion date: November 1, 2017
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 year old over

Exclusion Criteria:

• Non-life expectant Those who live longer than 24 hours not that consent

Related Conditions & MeSH terms

• Sepsis
• Toxemia

Locations

Country	Name	City	State
Turkey	Ataturk education research izmir	Izmir	Karabaglar

Sponsors (1)

Lead Sponsor	Collaborator
Izmir Ataturk Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	sepsis mortality		90 day